During the past decade, Tokyo Medical University Hospital conducted 51 clinical trials. In the 10-year time frame, 51 clinical trials started and 24 clinical trials were completed, i.e. on average, 47.1% percent of trials that started reached the finish line to date. In the past 5 years, 24 clinical trials started and 12 clinical trials were completed. i.e. 50% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Tokyo Medical University Hospital" #1 sponsor was "Hoffmann-La Roche" with 16 trials, followed by "Pfizer" with 11 trials sponsored, "Janssen Research & Development, LLC" with 5 trials sponsored, "Amgen" with 4 trials sponsored and "Celgene" with 4 trials sponsored. Other sponsors include 20 different institutions and companies that sponsored additional 24 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Tokyo Medical University Hospital" #1 collaborator was "Chugai Pharmaceutical" with 6 trials as a collaborator, "Kinki University" with 2 trials as a collaborator, "Tokyo Medical University" with 2 trials as a collaborator, "AbbVie" with 1 trials as a collaborator and "American Society for Gastrointestinal Endoscopy" with 1 trials as a collaborator. Other collaborators include 16 different institutions and companies that were collaborators in the rest 26 trials.

According to Clinical.Site data, the most researched conditions in "Tokyo Medical University Hospital" are "Alzheimer Disease" (6 trials), "Hemophilia A" (6 trials), "Dermatitis, Atopic" (3 trials), "Hemophilia B" (3 trials) and "Primary Myelofibrosis" (3 trials). Many other conditions were trialed in "Tokyo Medical University Hospital" in a lesser frequency.

Most popular intervention types in "Tokyo Medical University Hospital" are "Drug" (53 trials), "Biological" (9 trials), "Other" (6 trials), "Device" (4 trials) and "Procedure" (4 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (24 trials), "Cisplatin" (5 trials), "Apremilast" (4 trials), "Crovalimab" (3 trials) and "Emicizumab" (3 trials). Other intervention names were less common.

The vast majority of trials in "Tokyo Medical University Hospital" are 60 trials for "All" genders and 5 trials for "Male" genders.

Currently, there are NaN active trials in "Tokyo Medical University Hospital". undefined are not yet recruiting, 12 are recruiting, 17 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 23 completed trials in Tokyo Medical University Hospital, undefined suspended trials, and 11 terminated clinical trials to date.

Out of the total trials that were conducted in Tokyo Medical University Hospital, 4 "Phase 1" clinical trials were conducted, 16 "Phase 2" clinical trials and 43 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 4 trials that are defined as “Not Applicable".